Results 131 to 140 of about 5,576 (168)

Autoantibodies in Chagas' Cardiomyopathy and Arrhythmias

Autoimmunity, 2001
Pablo A Chiale
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Chagas cardiomyopathy and captopril

European Heart Journal, 1992
Chagas disease is a leading cause of heart failure in Latin America. Sudden death occurs in approximately 40% of patients with heart failure due to Chagas disease. We report a single blind, cross-over trial of prolonged treatment with captopril and placebo in 18 Chagas disease patients with class IV NYHA heart failure.
Roberti, Roberto Rinaldo UNIFESP, Martinez, E. E., Andrade, José Lazaro de UNIFESP, Araujo, V. L., Brito, Flavio Souza UNIFESP, Portugal, Oscar Pimentel UNIFESP, Horowitz, S. F.   +6 more
openaire   +3 more sources

Outcome of Chagas cardiomyopathy in comparison to ischemic cardiomyopathy

International Journal of Cardiology, 2013
Chagas cardiomyopathy and ischemic heart disease (IHD) are frequent causes of chronic systolic heart failure (CHF) in areas where the former is endemic. Nonetheless, a specific comparison of outcome and role of etiology of CHF failure has not been performed in patients with both conditions.Two-hundred twenty two patients with Chagas cardiomyopathy and ...
Augusto Cardinalli-Neto, Ana Paula Otaviano   +1 more
exaly   +3 more sources

Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy

New England Journal of Medicine, 2015
The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven.We conducted a prospective, multicenter, randomized study involving 2854 patients with Chagas' cardiomyopathy who received benznidazole or placebo for up to 80 days and were followed for a mean of 5.4 years. The primary outcome in the time-to-event analysis
Felipe Guhl, Antonio Mattos, Sérgio Sosa-Estani   +2 more
exaly   +4 more sources

An update on the management of Chagas cardiomyopathy

Expert Review of Anti-infective Therapy, 2007
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, infects nearly 18 million people in Latin America and mainly affects the heart, causing heart failure, arrhythmias, heart block, thromboembolism, stroke and death. In this review, the clinical diagnosis and management of Chagas cardiomyopathy are discussed.
Manoel O C, Rocha, Mauro M, Teixeira, Antonio L, Ribeiro   +2 more
openaire   +2 more sources

Heart transplantation for chagas' cardiomyopathy

The Annals of Thoracic Surgery, 1995
We present 2 patients who underwent orthotopic heart transplantation for end-stage Chagas' cardiomyopathy. Despite immunosuppressive therapy, postoperative prophylaxis with nifurtimox appeared to prevent Trypanosoma cruzi reactivation. Neither patient has shown signs of Chagas' myocarditis, and both are clinically well 12 and 72 months after ...
C, Blanche, I, Aleksic, J J, Takkenberg, L S, Czer, M C, Fishbein, A, Trento   +5 more
openaire   +2 more sources

Chagas’ cardiomyopathy

2018
Abstract Chagas’ cardiomyopathy is a major complication emerging from Trypanosoma cruzi infection, appearing in up to 30% of individuals with positive serology and being the principal cause of death from heart failure in some areas of South America.
Carlos Eduardo Rochitte, Otávio Rizzi Coelho-Filho   +1 more
openaire   +1 more source

Chagas cardiomyopathy and ischemic stroke

Expert Review of Cardiovascular Therapy, 2006
American trypanosomiasis, known as Chagas disease is a major cause of cardiomyopathy in South America. Irreversible damage to the heart can appear 10-20 years after chagasic infection. The relationship between Chagas cardiomyopathy and ischemic stroke has been reviewed.
openaire   +2 more sources

Chagas Cardiomyopathy in Latin America Review

Current Cardiology Reports, 2019
Chagas cardiomyopathy is a major public health disease in Latin America and, due to migration, is becoming a worldwide health and economic burden. This review sought to present the clinical and epidemiological aspects of Chagas cardiomyopathy, as well as some specific features and principles of treatment.
Juan Alberto Cosquillo Mejia, Jefferson Luis Vieira, Maria Gyslane Vasconcelos Sobral   +2 more
exaly   +3 more sources

Diagnosis and management of Chagas disease and cardiomyopathy

Nature Reviews Cardiology, 2012
Chagas cardiomyopathy is the most severe and life-threatening manifestation of human Chagas disease--a 'neglected' tropical disease caused by the protozoan parasite Trypanosoma cruzi. The disease is endemic in all continental Latin American countries, but has become a worldwide problem because of migration of infected individuals to developed countries,
Antonio L, Ribeiro, Maria P, Nunes, Mauro M, Teixeira, Manoel O C, Rocha   +3 more
openaire   +2 more sources